Integrated Investment Consultants LLC Has $1.70 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Key Points

• Integrated Investment Consultants LLC drastically reduced its stake in Eli Lilly and Company by 99.7%, selling 694,106 shares, leaving it with just 2,061 shares valued at approximately $1.7 million.
• Several other institutional investors have modified their positions in Eli Lilly, with some increasing their holdings by as much as 22% in the last quarter.
• Analyst ratings for Eli Lilly are generally positive, with 17 analysts rating it as a "buy" and a consensus price target of $1,012.56, despite a recent earnings report that missed expectations.

Integrated Investment Consultants LLC cut its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 99.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,061 shares of the company's stock after selling 694,106 shares during the quarter. Integrated Investment Consultants LLC's holdings in Eli Lilly and Company were worth $1,702,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Garner Asset Management Corp raised its position in shares of Eli Lilly and Company by 2.3% in the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after purchasing an additional 12 shares during the period. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Orion Capital Management LLC increased its position in Eli Lilly and Company by 2.5% during the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock worth $1,243,000 after acquiring an additional 40 shares during the period. Finally, Bank Pictet & Cie Europe AG increased its position in Eli Lilly and Company by 4.1% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock worth $49,993,000 after acquiring an additional 2,568 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 4.9%

Shares of LLY traded down $39.94 during mid-day trading on Tuesday, hitting $768.17. 3,732,558 shares of the company's stock were exchanged, compared to its average volume of 3,758,750. The company has a market cap of $728.03 billion, a PE ratio of 62.50, a P/E/G ratio of 1.18 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a 50-day simple moving average of $773.01 and a 200 day simple moving average of $800.67. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the business earned $2.58 earnings per share. Eli Lilly and Company's revenue was up 45.2% compared to the same quarter last year. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Guggenheim boosted their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.